Emerging Novel Cardiac MR Imaging Biomarkers in Cardiovascular Rare Disease Clinical Trials

Diagnostic and Interventional Cardiology, February 2026

Author: Rohit Sood, MD, PhD

Discover how advanced cardiac MRI biomarkers are reshaping rare cardiovascular disease research. This article explains how innovative imaging tools like LGE, T1/T2 mapping, ECV, and strain analysis allow earlier detection, more precise diagnosis, and better tracking of treatment response.

Authored by Rohit Sood, MD, PhD, it also highlights why consistent imaging standards are essential in multi‑center clinical trials, giving readers a concise look at the technology and practices driving smarter, more reliable cardiovascular research.

Why read this article:

• Learn how advanced cardiac MRI biomarkers are transforming rare cardiovascular disease research, enabling earlier detection, more accurate diagnosis, and deeper insight into disease mechanisms.
• Understand the real clinical impact of imaging innovations like LGE, T1/T2 mapping, ECV, and strain analysis, explained in practical, easy‑to‑grasp terms.
• See why these biomarkers are becoming essential endpoints in modern clinical trials, especially for conditions with small patient populations and high unmet needs.
• Gain insight into the operational challenges and best practices for implementing imaging consistently across multi‑center trials, ensuring high‑quality data that meets regulatory expectations.
• Hear directly from an expert in the field, Rohit Sood, MD, PhD, offers both scientific clarity and real-world perspective on emerging imaging technologies.

Learn more about Perceptive Imaging’s clinical trial imaging services here.